Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

GLP-1 prescriptions surge in US children

Analysis based on 8 articles · First reported Sep 04, 2026 · Last updated Sep 08, 2026

Sentiment
30
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study underscores the rapid expansion of GLP-1 drug use into pediatric populations, potentially broadening the market for Novo Nordisk and Eli Lilly and Company. Increased demand could boost revenues for these manufacturers, though concerns about access and long-term safety may influence regulatory and prescribing practices.

Pharmaceuticals Healthcare

A study led by NYU Langone Health, published in the journal Pediatrics on September 4, 2026, found that prescriptions for GLP-1 weight-loss drugs (Saxenda, Wegovy, Zepbound) among US children aged 8-11 with obesity increased 310-fold from 2019 to June 2026. The proportion rose from 0.03% to 9.3%, with over 20,000 children prescribed. Most had severe obesity and related conditions. The study highlighted an access gap, with children from upper-income communities 55% more likely to receive prescriptions. Researchers called for ensuring equitable access and long-term monitoring. Clinical trials are underway for children as young as 6.

stock
Manufacturer of Saxenda and Wegovy; rising pediatric prescriptions could expand market.
Importance 85.0 Sentiment 70.0
stock
Manufacturer of Zepbound; increased pediatric use may boost sales.
Importance 85.0 Sentiment 70.0
per
Lead investigator, publicly advocating for careful GLP-1 use in children.
Importance 70.0 Sentiment 20.0
per
Co-senior author, highlighted access disparities.
Importance 60.0 Sentiment 20.0
cnt
Obesity epidemic in children drives demand for treatments; policy implications.
Importance 50.0 Sentiment 10.0
priv
Provided data via Epic Cosmos; no role in study, but data source.
Importance 30.0 Sentiment 10.0
per
Co-investigator; disclosed honoraria.
Importance 20.0 Sentiment 0.0
priv
Orandi served on advisory board; not directly involved.
Importance 10.0 Sentiment 0.0
per
Co-investigator.
Importance 10.0 Sentiment 0.0
per
Co-investigator.
Importance 10.0 Sentiment 0.0
per
Co-investigator.
Importance 10.0 Sentiment 0.0
stock
Segev received honoraria; unrelated to study.
Importance 5.0 Sentiment 0.0
stock
Segev received honoraria; unrelated.
Importance 5.0 Sentiment 0.0
stock
Segev received honoraria; unrelated.
Importance 5.0 Sentiment 0.0
stock
Segev received honoraria; unrelated.
Importance 5.0 Sentiment 0.0
+ 5 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.